As a principal investigator at MGH, Price continues work to validate novel PET methods for imaging biological markers of health and disease in studies of aging and neurodegeneration, including studies of glucose metabolism, protein expression, neurotransmitter system function, and tau and amyloid beta plaque burden.

Upon completion of her bachelors, Price stayed at the University of Wisconsin-Madison to pursue her master's in medical physics[1] under the mentorship of Professor John Cameron.

She worked in the Radiation Calibration Service as a project specialist during her Master's where she explored the efficacy of diode dosimeters used to monitor radiotherapy doses.

[2] In 1985, during her Master's training, Price worked as a Summer Physics Research Assistant in the Diagnostic Radiology Department at the Mayo Clinic in Rochester, Minnesota,[1] learning to assess the level of radiation exposure to the fetus from multislice CT scans.

She later took part in a Yale-JHU collaboration to use Single Photon Emission Tomography to measure Benzodiazepine receptor concentration and affinity in the brains of non-human primates using a constant infusion paradigm, led by Drs.

[13] As Principal Investigator of the Price Lab at the Martinos Center for Biomedical Imaging, her translational collaborations extend into other areas.

[15] Her research also addresses race-based differences in disease as she explores the mechanisms of altered peripheral glucose uptake in African American women.

[16] Price played an integral role in the kinetic evaluation of the Pittsburgh Compound B, and establishing its use for imaging amyloid beta plaques in living human brain.

[20] This work represents early critical steps that supported the use of PiB retention as a stable and valid in vivo marker of amyloid beta AD neuropathology and helped to establish this new and rapidly growing field of research.